These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29651918)

  • 41. Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study.
    Soga T; Kume K; Kakuta N; Hamaguchi E; Tsutsumi R; Kawanishi R; Fukuta K; Tanaka K; Tsutsumi YM
    J Anesth; 2015 Oct; 29(5):696-701. PubMed ID: 25801542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
    J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fosaprepitant versus droperidol for prevention of PONV in craniotomy: a randomized double-blind study.
    Atsuta J; Inoue S; Tanaka Y; Abe K; Nakase H; Kawaguchi M
    J Anesth; 2017 Feb; 31(1):82-88. PubMed ID: 27757553
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Appropriate dosing of fosaprepitant for colon cancer patients].
    Aimono Y; Sakuyama K; Suzuki S; Nemoto M; Saito Y; Aoyama Y; Joko F; Maruyama T; Kamoshida T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):211-3. PubMed ID: 25743141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
    Tsuda T; Kyomori C; Mizukami T; Taniyama T; Izawa N; Horie Y; Hirakawa M; Ogura T; Nakajima TE; Tsugawa K; Boku N
    Mol Clin Oncol; 2016 Apr; 4(4):603-606. PubMed ID: 27073673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.
    Kitayama H; Tsuji Y; Sugiyama J; Doi A; Kondo T; Hirayama M
    Int J Clin Oncol; 2015 Dec; 20(6):1051-6. PubMed ID: 25822106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects.
    Marbury TC; Ngo PL; Shadle CR; Jin B; Panebianco D; Caro L; Valentine J; Murphy G
    J Clin Pharmacol; 2011 Dec; 51(12):1712-20. PubMed ID: 21209230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infusion reactions following administration of intravenous rolapitant at an academic medical center.
    Cass AS; Odinet JS; Valgus JM; Crona DJ
    J Oncol Pharm Pract; 2019 Oct; 25(7):1776-1783. PubMed ID: 30348072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Opin Pharmacother; 2016 Aug; 17(12):1623-9. PubMed ID: 27322893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IV aprepitant (Cinvanti) for chemotherapy-induced nausea and vomiting.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):e200-e201. PubMed ID: 30653479
    [No Abstract]   [Full Text] [Related]  

  • 51. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas.
    Tsukahara K; Nakamura K; Motohashi R; Sato H; Endo M; Katsube Y; Ueda Y; Suzuki M
    Acta Otolaryngol; 2014 Nov; 134(11):1198-204. PubMed ID: 25315920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
    Choi MR; Jiles C; Seibel NL
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):e268-71. PubMed ID: 20736848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy.
    Uchida M; Ikesue H; Kato K; Ichinose K; Hiraiwa H; Sakurai A; Takenaka K; Iwasaki H; Miyamoto T; Teshima T; Egashira N; Akashi K; Oishi R
    Am J Health Syst Pharm; 2013 Feb; 70(4):343-9. PubMed ID: 23370141
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice.
    Dushenkov A; Kalabalik J; Carbone A; Jungsuwadee P
    J Oncol Pharm Pract; 2017 Jun; 23(4):296-308. PubMed ID: 26921085
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients.
    Sato Y; Kondo M; Inagaki A; Komatsu H; Okada C; Naruse K; Sahashi T; Kuroda J; Ogura H; Uegaki S; Yoshida T; Mori Y; Sawada H; Watanabe S; Sugiura H; Endo Y; Yoshimoto N; Toyama T; Iida S; Yamada K; Kimura K; Wakita A
    J Cancer; 2014; 5(5):390-7. PubMed ID: 24799957
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relieving nausea and vomiting in patients with cancer: a treatment algorithm.
    Johnson MH; Moroney CE; Gay CF
    Oncol Nurs Forum; 1997; 24(1):51-7. PubMed ID: 9007907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiemetic agents.
    Wilkes G
    Oncology (Williston Park); 2007 Jul; 21(8 Suppl):48. PubMed ID: 17844897
    [No Abstract]   [Full Text] [Related]  

  • 60. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.
    Van Laere K; De Hoon J; Bormans G; Koole M; Derdelinckx I; De Lepeleire I; Declercq R; Sanabria Bohorquez SM; Hamill T; Mozley PD; Tatosian D; Xie W; Liu Y; Liu F; Zappacosta P; Mahon C; Butterfield KL; Rosen LB; Murphy MG; Hargreaves RJ; Wagner JA; Shadle CR
    Clin Pharmacol Ther; 2012 Aug; 92(2):243-50. PubMed ID: 22739139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.